Alanylglutamine-assisted Antimicrobial Agent Treatment Improves the Efficacy of Severe Pneumonia and Its Effect on SP-A, SP-D and Humoral Immunity

OBJECTIVE To explore the effects of alanylglutamine combined with antimicrobial agent on pulmonary surfactant protein-A(SP-A), pulmonary surfactant protein-D(SP-D) and humoral immunity in patients with severe pneumonia. METHODS A total of 97 patients with severe pneumonia treated in Nanjing Integrated Traditional Chinese and Western Medicine Hospital from January 2016 to December 2018 were selected as subjects of study, the patients were divided into observation group(n=51) and control group(n=46) according to the method of random number table, the control group received antimicrobial agent treatment(meropenem), the observation group was treated with alanylglutamine intravenously on the basis of the control group. To compare the clinical total effective rate, arterial partial pressure of oxygen(PaO₂), partial pressure of carbon dioxide(PaCO₂) and oxygen saturation(SpO₂), SP-A, SP-D, immunoglobulin A(IgA), immunoglobulin M(IgM) and immunoglobulin G(IgG) and adverse reactions occur. RESULTS The total effective rate of the observation group was significantly higher than that of the control group(P<0.05). The PaO₂ and SpO₂ values of the two groups were significantly higher than those before treatment(P<0.05), and the PaO₂ and SpO₂ values of the observation group were significantly higher than those of the control group(P<0.05). The PaCO₂ values of the two groups were significantly lower than those before treatment(P<0.05), and the PaCO₂ values of the observation group were significantly lower than those of the control group(P<0.05). The levels of SP-A and SP-D in the two groups were significantly higher than those before treatment(P<0.05), and the levels of SP-A and SP-D in the observation group were significantly higher than those in the control group(P<0.05). The levels of IgA, IgG and IgM in the two groups were significantly higher than those before treatment(P<0.05), and the levels of IgA and IgG in the observation group were significantly higher than those in the control group(P<0.05), while the levels of IgM in the control group were significantly higher than those in the observation group(P<0.05). After treatment, 2 patients in the control group developed vomiting symptoms and 3 patients developed diarrhea. No adverse reactions were found in the observation group. CONCLUSION The combined treatment of alanylglutamine and antimicrobial agent can improve the oxygenation ability of severe pneumonia patients, improve their immunity and inhibit the occurrence of inflammatory reaction.